(Q39007008)

8 September 2017

title

Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use. (English)

1 reference

8 September 2017

1 reference

Emanuele Focà

1

1 reference

8 September 2017

Diego Ripamonti

series ordinal

2

1 reference

8 September 2017

Davide Motta

series ordinal

3

1 reference

8 September 2017

Carlo Torti

series ordinal

4

1 reference

8 September 2017

publication date

1 June 2012

1 reference

8 September 2017

1 reference

8 September 2017

volume

72

1 reference

8 September 2017

issue

9

1 reference

8 September 2017

page(s)

1161-1173

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Atazanavir: a review of its use in the management of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Atazanavir pharmacokinetics with and without tenofovir during pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Efficacy and safety of atazanavir in patients with end-stage liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Review and management of drug interactions with boceprevir and telaprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Factors influencing lopinavir and atazanavir plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11631070-000000000-00000

FDA notifications. FDA approves new atazanavir labeling

21 January 2018

1 reference

12 December 2020

Simplification strategies to reduce antiretroviral drug exposure: progress and prospects

1 reference

12 December 2020

A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults

1 reference

12 December 2020

A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results

1 reference

12 December 2020

Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study

1 reference

12 December 2020

Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra

1 reference

12 December 2020

Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients

1 reference

12 December 2020

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

1 reference

12 December 2020

Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

1 reference

12 December 2020

Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience

1 reference

12 December 2020

Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients

1 reference

12 December 2020

Use of HIV protease inhibitors as pharmacoenhancers

1 reference

12 December 2020

10.2165/11631070-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

8 September 2017

1052037427

0 references

1 reference